publication venue for
- Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin-12/B7.1 genes 2001
- Redirecting genetically engineered effector lymphocytes to cancer using chimeric receptors 2000
- Combination therapy with IL-2 and wild-type p53 expressed by Ad-vectors induces tumor regression in vivo without cytokine related toxicity 1997
- A high capacity adenovirus vector with all viral genes deleted results in improved in vivo expression and decreased toxicity 1997
- Interleukin-12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression 1997
- Tumour immunotherapy using an adenoviral vector expressing a membrane bound mutant of murine TNF 1997
- Activated Src requires Cadherin-11, Rac, and gp130 for Stat3 activation and survival of mouse Balb/c3T3 fibroblasts. 29:1502-1513. 2022
- AAV-mediated expression of 3TSR inhibits tumor and metastatic lesion development and extends survival in a murine model of epithelial ovarian carcinoma. 27:356-367. 2020
- Oncolytic bovine herpesvirus type 1 infects and kills breast tumor cells and breast cancer-initiating cells irrespective of tumor subtype. 20:282-289. 2013
- HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice. 19:888-898. 2012
- Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. 19:238-246. 2012
- Bovine herpesvirus type 1 as a novel oncolytic virus. 17:344-355. 2010
- High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome. 16:338-350. 2009
- Sensitivity of 5-fluorouracil-resistant cancer cells to adenovirus suicide gene therapy. 14:57-65. 2007
- A multiprong approach to cancer gene therapy by coencapsulated cells. 12:369-380. 2005
- A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. 10:755-763. 2003
- Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor. 9:778-786. 2002
- Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: Preclinical studies in myeloma. 8:361-370. 2001
- Activation of host antitumoral responses by cationic lipid/DNA complexes. 7:353-359. 2000
- A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor α expressed from an adenovirus vector induces an antitumor response with reduced toxicity. 6:465-474. 1999
- Autologous lymphocyte responses to adenovirus-B7-1-transduced human cancer cells. 6:195-208. 1999